Horizon trial

Study / Research

A cardiovascular outcomes trial launched by Ionis/Novartis to study the effect of their antisense oligonucleotide on preventing major atherosclerotic cardiovascular events in patients with stable cardiovascular diseases.

Mentioned in 1 video

Videos Mentioning Horizon trial

210 - Lp(a) and its impact on heart disease | Benoît Arsenault, Ph.D.& Peter Attia, M.D.

210 - Lp(a) and its impact on heart disease | Benoît Arsenault, Ph.D.& Peter Attia, M.D.

Peter Attia MD

A cardiovascular outcomes trial launched by Ionis/Novartis to study the effect of their antisense oligonucleotide on preventing major atherosclerotic cardiovascular events in patients with stable cardiovascular diseases.